Halozyme prelim FY2023 revenue $827-832M; GAAP EPS $2.18-2.21

HALOZYME THERAPEUTICS, INC.

2023-FY EPS reported $2.10 revenue$829,253,000

Revenue estimated $827-832M; royalties $445-450M for FY2023.
Net income $292-297M; EBITDA $435-440M; adjusted EBITDA $425-430M.
GAAP diluted EPS $2.18-2.21; non-GAAP diluted EPS $2.77-2.80.
Preliminary unaudited estimates subject to completion of year-end close.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HALOZYME THERAPEUTICS, INC. reported Twelve Months Ended December 31, 2023 results: revenue $827 million to $832 million, net income $292 million to $297 million, EPS GAAP Diluted EPS $2.18 to $2.21 ; Non-GAAP Diluted EPS $2.77 to $2.80.

Period: Twelve Months Ended December 31, 2023
Revenue: $827 million to $832 million
Net income: $292 million to $297 million
EPS: GAAP Diluted EPS $2.18 to $2.21 ; Non-GAAP Diluted EPS $2.77 to $2.80
Result: preliminary results

Exact text from the filing

this preliminary information. Unaudited Preliminary Estimates of Results for the Twelve Months Ended December 31, 2023 The Company estimates 2023 Revenue will be in the range of $827 million to $832 million. The Company estimates 2023 royalties will be in the range of $445 million to $450 million. The Company estimates 2023 Net Income will be in the range of $292

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.